Latest news with #www.CastleBiosciences.com
Yahoo
5 days ago
- Business
- Yahoo
Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful organizationsFRIENDSWOOD, Texas, July 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal. This prestigious honor celebrates leaders who have demonstrated outstanding financial stewardship, fostered inclusive and thriving workplace cultures, and made meaningful contributions to the greater Houston community. 'Derek's visionary leadership and unwavering values have shaped Castle Biosciences into what it is today: a company focused on improving patient outcomes through innovative diagnostic tests for skin cancers, Barrett's esophagus and uveal melanoma,' said Frank Stokes, chief financial officer of Castle Biosciences. 'Over nearly two decades, his leadership approach has exemplified how great vision and values can drive meaningful progress – building a company culture where patient needs remain at the center of strategic decisions and where personalized disease insights can translate into better care for those who need it most.' 'I am truly honored to receive this recognition from the Houston Business Journal,' said Maetzold. "This award validates our core belief that lasting impact comes from doing right by our team and never losing sight of the patients who depend on our work.' The award recipients will be honored at a special event held by the Houston Business Journal in August. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@ Source: Castle Biosciences Inc. Photos accompanying this announcement are available at: in to access your portfolio
Yahoo
11-06-2025
- Business
- Yahoo
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, founder, president and chief executive officer of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during the 2025 BIO International Convention (BIO 2025), being held June 16-19 in Boston. The panel will explore the challenges precision medicine companies face in commercializing innovative diagnostic tests and discuss strategies for navigating today's market complexities while remaining focused on improving care for patients. Panel Details:Title: Advancing Innovative Risk-Stratification Tests That Impact Treatment Pathway Decisions: Challenges in Overcoming Barriers to EntryDate & Time: Tuesday, June 17, 2025, from 11 a.m.-12 p.m. Eastern TimeLocation: Room 251Focus Area: Diagnostics and Personalized MedicineSession Type: Breakout Session Moderator: Michael Ryan, J.D., Partner, McDermott Will & EmeryPanel Participants: Mara Aspinall, Partner, Illumina Ventures Gillian Hooker, Ph.D., ScM, CGC, Chief Scientific Officer, Concert Derek Maetzold, Founder, President and CEO, Castle Biosciences Castle is also a member of the City of Phoenix and Texas delegations attending BIO 2025. For information on Castle, please visit the City of Phoenix Pavilion (1639) or the Texas Pavilion (2665). To register to attend BIO 2025, visit About BIO BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@ Source: Castle Biosciences Inc.
Yahoo
21-05-2025
- Business
- Yahoo
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time. A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at A replay of the webcast will be available following the conclusion of the live broadcast. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@ Source: Castle Biosciences in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time. A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at A replay of the webcast will be available following the conclusion of the live broadcast. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@ Source: Castle Biosciences Inc.
